Research Reveals Genetic Link to Most Common Pediatric Bone Cancer

Translate to Spanish or other 102 languages!

Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. Image for illustration purposes
Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. Image for illustration purposes
- Advertisement -

CLEVELAND CLINIC – Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. 

“Osteosarcoma is a very malignant, aggressive cancer that has a poor prognosis. And thus far, it doesn’t have a lot of genes that we can test for that would tell you that you’re at risk for this cancer. Well, SMARCAL1 one happens to be one of those genes that we can now actually test for in families that have history of cancers, or history of this particular osteosarcoma cancer,” said Richa Sharma, MD, hematologist and oncologist at Cleveland Clinic Children’s.

Dr. Sharma, who led the research, said they analyzed genetic information from nearly 6,000 children with cancer and compared it to more than 14,000 adults with cancer. 

- Advertisement -

Ultimately, they found one gene in particular had a significant risk factor for osteosarcoma. 

In addition, approximately 2.6% of children with osteosarcoma had inherited mutations of that gene, which Dr. Sharma said may weaken DNA repair and promote tumor growth. 

She explained that these findings could be helpful not only for future risk assessment but also for potential therapies. 

“From a therapy perspective, this is where scientists really need to collaborate and get together and understand how SMARCAL1 drives tumor biology, because that is how you’re going to achieve targetable therapies. And so, it has bigger potential, but the science is behind. We need to catch up now and try to connect the dots,” said Dr. Sharma. 

- Advertisement -

Reports show that fewer than 1,000 people in the United States develop osteosarcoma each year. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -